SCHEMBL20103471

SCHEMBL20103471

CCOC(=O)C1CCC(=O)C=C1CC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.43
ALDH1A1 P00352 9/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
MAPT P10636 5/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 2/20 0.40
RECQL P46063 1/20 0.39
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
POLB P06746 2/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9470405 0.81 TLR4 (0.43) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL24249958 0.79 TLR4 (0.49) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL17118109 0.79 TLR4 (0.49) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL1141761 0.79 TLR4 (0.49) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL9753067 0.76 MEN1 (0.50) TLR4ALDH1A1MEN1KMT2APOLB
SCHEMBL7634605 0.74 CHRM2 (0.50) TLR4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL7633659 0.74 MEN1 (0.46) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL7638589 0.72 TLR4 (0.41) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL7634499 0.72 ALDH1A1 (0.44) TLR4ALDH1A1MEN1KMT2AMAPT
SCHEMBL7642686 0.72 ALDH1A1 (0.46) TLR4ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2021-04-27 US disclosed
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN RESEARCH & DEVELOPMENT, LLC 2020-02-06 US disclosed
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GPR65, GPR55 TLR4 259/4885ALDH1A1 2898/4885MEN1 4514/4885
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes GPR119, GPR65, GPR55 TLR4 259/4885ALDH1A1 2898/4885MEN1 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.